When Kailera Therapeutics priced its IPO at $16 per share on Thursday evening, it was already doing something that hadn’t happened in the biotech sector in five years: raising $625 million in a single public market debut. When trading opened Friday morning on the Nasdaq Global Select Market, the stock climbed straight to $26 and closed there — a 62.5% gain on its first day, pushing the Waltham-based company’s market capitalization past $3 billion before it has earned a dollar in product revenue.
The last biotech to pull off a debut this large was Sana Biotechnology in 2021, when it raised $676 million. The IPO window has been largely closed for clinical-stage companies since then. Kailera opening it back up — and with this kind of first-day response — says something about where investor appetite currently sits. And where it sits is firmly in the obesity drug space, the one market in pharma that has demonstrated in the last two years that the demand for effective weight-loss treatments is essentially limitless.
Kailera was founded in 2024 — barely two years ago — by a team that licensed four clinical-stage GLP-1 based drug candidates from Jiangsu Hengrui Pharmaceuticals, one of China’s largest drugmakers, retaining exclusive rights to develop and commercialize them outside of Greater China. Its lead candidate is ribupatide, a once-weekly injectable dual GLP-1/GIP receptor agonist currently running through three global Phase 3 trials that began between December 2025 and January 2026. In a Phase 2 trial in China, Hengrui’s data showed nearly 18% mean weight loss at 48 weeks — a number that would put it in competitive territory with Eli Lilly’s tirzepatide, the most prescribed weight-loss drug on the market.
The company is not stopping at a weekly injection. Its pipeline includes oral ribupatide — a once-daily tablet using the same peptide as the injectable — as well as KAI-7535, a once-daily small-molecule GLP-1 agonist, and KAI-4729, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously for patients who need greater weight reduction. That last candidate targets a specific problem the existing drugs have not solved: in the landmark SURMOUNT-1 trial for tirzepatide, 68% of participants with a BMI above 35 were still living with obesity at the end of 72 weeks of treatment. Kailera’s thesis is that those patients need something more potent, and that a diversified pipeline — injectable and oral, dual and triple mechanism — is the right way to serve an obesity population that is far from homogeneous.
The company’s CEO is Ron Renaud, who previously led Cerevel Therapeutics through its $8.7 billion acquisition by AbbVie in 2024. Bain Capital Private Equity and Bain Capital Life Sciences are the largest institutional shareholders, owning roughly a third of the company after the offering, and the Qatar Investment Authority participated alongside existing investors. J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, and Evercore ISI served as joint book-running managers.
Kailera posted a net loss of $149 million in 2025 and spent 2024 burning through capital at an even faster pace while building out its clinical infrastructure from scratch. The company has no approved products and will not have revenue until, at earliest, the late 2020s if the Phase 3 trials succeed and regulators approve. The $625 million raised, combined with existing cash, is earmarked to fund the three ribupatide Phase 3 trials through the second quarter of 2028.
The obesity drug market that Kailera is entering is projected to reach $200 billion by 2030. Eli Lilly and Novo Nordisk — the makers of tirzepatide and semaglutide respectively — currently dominate, but both are constrained by manufacturing capacity and supply chain bottlenecks that have left demand consistently outpacing availability. The theory behind Kailera, and behind the investors who pushed this IPO to oversubscribed status, is that there is room for a well-capitalized challenger with a differentiated pipeline — particularly one with data that suggests superior weight loss at the doses most patients actually need.
Whether the Phase 3 data matches the Phase 2 promise is the only question that matters now.
